Mucoepidermoid (MEC) salivary gland tumors arise from a t(11;19) rearrangement which generates a fusion oncogene, Mect1-Maml2, that functions to activate CREB-responsive target genes. To determine if sustained expression of Mect1-Maml2 is required for tumor cell growth, we first showed that ectopic expression of Mect1-Maml2 in rat epithelial RK3E cells is tumorigenic in vivo in nude mice and that excised xenografts continue to express the fusion oncogene. We then generated a hairpin RNAi vector that selectively suppressed the fusion peptide and showed that ectopic expression in either parotid or pulmonary MEC tumor cell lines containing the t(11;19) rearrangement resulted in at least 90% colony growth inhibition. In contrast, single nucleotide changes within this RNAi sequence abolished the ability to suppress Mect1-Maml2 protein and abolished all growth inhibition of these MEC tumor lines. In addition, the RNAi-specific vector had no effect on colony growth of non-MEC tumors including a lung tumor or two other salivary gland cell lines that do not express Mect1-Maml2. We also generated a mutant Mect1-Maml2 expression plasmid that carried silent nucleotide changes within the RNAi target sequence and observed that co-transfection of this mutant, but not wild-type Mect1-Maml2, could partially rescue RNAi growth inhibition in the MEC tumor line. The recent detection of acquired fusion oncogenes in epithelial solid tumors has suggested new possibilities for the diagnosis and therapy of these cancers. Our data show that the 'gain-of-function' activity from aberrant Mect1-Maml2 expression is a candidate therapeutic target for this group of malignant salivary gland tumors.
Mucoepidermoid (MEC) salivary gland tumors arise from a t(11;19) rearrangement which generates a fusion oncogene, Mect1-Maml2, that functions to activate CREB-responsive target genes. To determine if sustained expression of Mect1-Maml2 is required for tumor cell growth, we first showed that ectopic expression of Mect1-Maml2 in rat epithelial RK3E cells is tumorigenic in vivo in nude mice and that excised xenografts continue to express the fusion oncogene. We then generated a hairpin RNAi vector that selectively suppressed the fusion peptide and showed that ectopic expression in either parotid or pulmonary MEC tumor cell lines containing the t(11;19) rearrangement resulted in at least 90% colony growth inhibition. In contrast, single nucleotide changes within this RNAi sequence abolished the ability to suppress Mect1-Maml2 protein and abolished all growth inhibition of these MEC tumor lines. In addition, the RNAi-specific vector had no effect on colony growth of non-MEC tumors including a lung tumor or two other salivary gland cell lines that do not express Mect1-Maml2. We also generated a mutant Mect1-Maml2 expression plasmid that carried silent nucleotide changes within the RNAi target sequence and observed that co-transfection of this mutant, but not wild-type Mect1-Maml2, could partially rescue RNAi growth inhibition in the MEC tumor line. The recent detection of acquired fusion oncogenes in epithelial solid tumors has suggested new possibilities for the diagnosis and therapy of these cancers. Our data show that the 'gain-of-function' activity from aberrant Mect1-Maml2 expression is a candidate therapeutic target for this group of malignant salivary gland tumors. Keywords: mucoepidermoid cancer; salivary gland cancer; chromosomal translocation; RNAi Mucoepidermoid cancer (MEC) is the most common malignant salivary gland tumor, arising within major or minor glands throughout the upper aerodigestive tract, with an estimated incidence of approximately 1000 cases/year in the United States (Speight and Barrett, 2002) . These, and other related tumors, are associated with a t(11;19) translocation that generates a chimeric peptide composed of 42 codons from Mect1 exon 1 which is fused in-frame with 981 codons from the carboxyl-terminal exons 2-5 of the Maml2 gene (Tonon et al., 2003; Enlund et al., 2004a; Behboudi et al., 2005) . The importance of the t(11;19) translocation in these tumors was suggested by the observation that the t(11;19) rearrangement was the sole cytogenetic alterations in several tumor samples (El-Naggar et al., 1996; Stenman et al., 1998; Martins et al., 2004) , by the ability of Mect1-Maml2 to induce foci formation in rat RK3E epithelial cell in vitro (Tonon et al., 2003; Coxon et al., 2005; Wu et al., 2005) , and by the detection of Mect1-Maml2 in 50-70% of mucoepidermoid tumors studied to date (Roberts et al., 2003; Tonon et al., 2003; Enlund et al., 2004a, b; Martins et al., 2004) . Although the biological role of this fusion oncopepetide in cancer development is still undefined, a current model for Mect1-Maml2-mediated tumorigenesis suggests that the fusion peptide functions to aberrantly activate a set of CREB/cAMP regulated genes (Coxon et al., 2005; Wu et al., 2005) . As there has been recent interest in the unexpected detection of fusion oncogenes in epithelial solid tumors (Tognon et al., 2002; Mitelman et al., 2004; Tomlins et al., 2005) , we wished to determine if this tumor could serve as a useful epithelial model system for testing novel approaches directed against a unique, pathogenic molecular marker.
We have previously shown that ectopic expression of Mect1-Maml2 induces foci formation in RK3E cells in vitro, while in-frame deletions within the N-terminal Mect1 domain abolished this foci activity (Tonon et al., 2003; Coxon et al., 2005) . To determine the tumorigenicity of the Mect1-Maml2 gene in vivo, we transfected RK3E cells with an empty CMV promoter plasmid vector, the full-length Maml2 cDNA, a truncated Maml2 (only exons 2-5), or with the Mect1-Maml2 chimeric cDNA. Following a 4-week incubation in the absence of selection media, we detected foci formation with Mect1-Maml2 transfected cells, but not with the control transfected cells, as previously published (Coxon et al. (2005) , Tonon et al. (2003) and data not shown). We pooled and expanded the RK3E cells from the vector alone, the truncated Maml2, and the Mect1-Maml2 transfected RK3E plates and injected 5 Â 10 5 cells into the flanks of athymic nude mice. We detected tumor formation within 14 days in 5/5 mice using Mect1-Maml2 transfected cells, but no xenograft tumor formation was detected at 3 months in 30 mice from any of the control transfected cells (Po0.001; Figure 1a ). We excised a xenograft tumor from a mouse injected with Mect1-Maml2 transfected cells and harvested total RNA to determine if persistent Mect1-Maml2 expression was present in the expanded tumor in vivo. We detected the Mect1-Maml2 transcript by reverse transcriptase-PCR in the xenograft tumor, while no signal was detected in RNA from the parental RK3E cells or from control transfected cell lines (Figure 1b ). These data demonstrates that Mect1-Maml2 can efficiently transform RK3E cells in vivo, resulting in tumors at 14 days in 100% of injected mice. In addition, the persistent detection of Mect1-Maml2 cDNA within the xenograft tumor suggests that sustained expression of Mect1-Maml2 is required for tumorigenicity in vivo in this mouse model. Further evidence for the importance of Mect1-Maml2 expression in the tumorigenicity and continued viability of human mucoepidermoid tumors can also be inferred from the detection of the fusion oncogene in the H292 and H3118 MEC tumor cell lines (Tonon et al., 2003) that were derived from patient biopsy samples obtained 22 and 10 years ago, respectively, and which have undergone extensive population doublings in our laboratory. We recently obtained an additional MEC tumor cell line, designated UT-MUC-1 (a kind gift from Dr Grenman), which was generated 15 years ago from a patient with a poorly differentiated mucoepidermoid carcinoma (Grenman et al., 1992) and, using RT-PCR methods (Tonon et al., 2003) , we also detected the Mect1-Maml2 fusion transcript (data not shown). Therefore, while there have been only three MEC tumor cell lines isolated and reported to date, the presence of sustained Mect1-Maml2 expression in each case suggests an important role in maintaining tumor cell growth.
To test the biological effect of blocking Mect1-Maml2 in salivary gland tumor cells that endogenously express the fusion oncopeptide, we designed several RNAi sequences for transfection using the pSHAG hairpin RNAi vector system. To test the ability of these sequences to block Mect1-Maml2 expression, we cotransfected a Mect1-Maml2 expression plasmid that contained an N-terminal FLAG peptide epitope (pFLAG-CMV2) with either an empty pSHAG vector or with a pSHAG vector containing different candidate RNAi hairpin nucleotide sequences (Figure 2a ). Seventy-two hours post-transfection, cells were harvested and protein lysates were subjected to immunoblot analysis using an anti-FLAG antibody to score for steady-state Mect1-Maml2 protein levels. Although we were unable to identify a hairpin nucleotide sequence spanning the fusion domain that might selectively 'knock down' the fusion transcript (RNAi sequence no. 1 and no. 2; Figure 2 and data not shown), we identified a nucleotide sequence adjacent to the fusion domain within the Maml2 sequence (designated as vector alone 0/15
Figure 1 (a) Athymic nude mice were injected subcutaneously with 5 Â 10 5 RK3E cells that were pooled following transfection with either vector alone, truncated Maml2 (exons 2-5), or Mect1-Maml2 as previously described (Tonon et al., 2003; Coxon et al., 2005) . Mice injected with vector or truncated Maml2 cells were observed for 3 months. 
Tumor growth in salivary gland cancers T Komiya et al
RNAi clone no. 4) which could efficiently block (>99%) Mect1-Maml2 protein expression (Figure 2b and c). In contrast, the RNAi sequence no. 4 had no effect on the steady-state levels of alpha-tubulin or PARP protein in these cells suggesting specific mRNA targeting. To confirm the specificity of clone no. 4, we introduced single nucleotide changes into the no. 4 sequence (designated no. 4 mt1 and mt 2) and showed that these mutant plasmid sequences could no longer block Mect1-Maml2 protein expression (Figure 2c ). As the clone no. 4 sequence overlapped with Maml2 exon 2 sequences we demonstrated that transfection of this pSHAG plasmid also downregulated the expression of a co-transfected wild-type Maml2 expression plasmid, but not the related homologue, Maml1 (data not shown).
To test the ability of pSHAG no. 4 to inhibit the colony growth of salivary gland tumor cells that carry the t(11;19) translocation, we transfected into MEC tumor cell lines the pSHAG clone no. 4 or control plasmids which included the empty pSHAG vector (vec), a firefly luciferase sequence (FF), or the related pSHAG RNAi clones no. 3 and RNAi no. 4 mt1 which were inactive in inhibiting Mect1-Maml2 protein expression (Figure 3 and data not shown). As RNAi clone no. 4 may suppress expression of the normal Maml2 gene product, we included an additional control for specificity by testing the effect of these RNAi vectors on two different immortalized non-MEC salivary gland cell lines (HSY and HSG) and on a lung carcinoma cell line (H2009) that do not express the Mect1-Maml2 protein.
We observed that the pSHAG clone no. 4 sequence had a marked effect on the inhibition of colony formation in both MEC cell lines, H292 and H3118, while the related control plasmids, including vector alone, FF-luciferase, RNAi clone no. 3, and clone no. 4 mt1 had no effect on the colony growth of either MEC cell line (Figure 3 and data not shown). Importantly, the specific RNAi clone no. 4 had no effect on colony growth of either the H2009 lung adenocarcinoma cell line or of the HSY and HSG salivary gland cell lines. To confirm that the lack of growth inhibition with these non-MEC salivary gland cells was not due to unsuccessful transfection of the pSHAG RNAi vector in these cells, we harvested DNA from several single HSY-transfected colonies and detected stable vector expression from each independent colony (Figure 3d) . The slightly larger, slower migrating PCR species in DNA from the single HSY colonies transfected with RNAi clone no. 4, as compared with pSHAG vector alone, reflects the inserted Mect1-Maml2 hairpin nucleotide sequence. The absence of growth inhibition in these non-MEC cells, despite the targeting of the Maml2 gene by RNAi clone no. 4, may be attributed to the redundant activity of two other mastermind-like genes, Maml1 and Maml3 (Lin et al., 2002; Wu et al., 2002) and to the observation that steady-state Maml1 levels are considerably higher than Maml2 levels in a wide range of mammalian tissues (Lin et al., 2002) . These data, therefore, suggest that downregulation of Maml2 will not be toxic to normal tissues or non-MEC tumor cells. In summary, we observed that the inhibitory effect of the RNAi vector is restricted to tumor cells that express Mect1-Maml2. This observation, combined with the persistent expression of Mect1-Maml2 in nude mouse tumor xenografts, also suggests that these mucoepidermoid tumor cell lines are dependent on the sustained expression of Mect1-Maml2 for viability. Conversely, our data demonstrates that inhibition of Mect1-Maml2 expression with a sequence-specific RNAi vector results in marked growth (Figure 4 ). As these changes do not alter the amino-acid sequence, the resulting expression plasmid is expected to retain biological activity which may not be as efficiently blocked by the RNAi vector clone no. 4. We examined the ability of the RNAi clone no. 4 to repress expression of the mutant plasmid (designated Mect1-Maml2**) by co-transfection into H2009 lung cells followed by immunoblotting for the tagged Mect1-Maml2 species at 72 h. As predicted, we showed that wild-type protein, but not the Mect1-Maml2** mutant, could be inhibited by the sequence specific RNAi vector. Since expression of the RNAi clone no. 4 is strongly inhibitory to MEC tumor cell colony growth, we tested the ability of the Mect1-Maml2** to partially rescue this inhibition by transfecting the indicated plasmids into H292 MEC tumor cells. As expected, 6 mg of RNAi no. 4 cotransfected with a CMV parental control vector suppressed H292 colony growth as compared with the inactive RNAi no. 3 vector. Although co-transfection of RNAi no. 4 with the wild-type Mect1-Maml2 (which can be suppressed by the RNAi sequence) showed no enhancement of colony growth, we observed a small, two-fold, increase of the colony inhibition phenotype by transfecting the M-M2** plasmid (Figure 4b ). As the RNAi plasmid was strongly inhibitory under these cotransfection conditions, we lowered the amount of the transfected pSHAG RNAi vector to enhance the ability of the fusion oncogene to rescue growth inhibition. Although the wild-type M-M2 was still unable to rescue growth inhibition, we observed a three-fold increase in colony counts using the co-transfected M-M2** vector. This observation adds additional support for the hypothesis that Mect1-Maml2 is participating in the growth deregulation of these cells and that it is a specific target for the RNAi vector.
These data, combined with the observations (i) that the RNAi no. 4 clone had no effect on colony growth of salivary gland (HSY and HSG) and lung cancer (H2009) cells that do not express Mect-Maml2 and (ii) that point mutants within the clone no. 4 sequence abolished the growth inhibitory effect on the H292 and H3118 MEC tumor lines, strengthen the evidence for the specificity of the RNAi vector and that sustained Mect1-Maml2 is essential for tumor viability. In addition, these data suggest that Mect1-Maml2 is a plausible therapeutic target for malignant salivary gland tumors that contain the t(11;19) chromosomal rearrangement. Alternate therapeutic strategies could also include efforts to exploit the recently proposed model that Mect1-Maml2 functions to deregulate cAMP signaling (Conkright et al., 2003; Iourgenko et al., 2003; Coxon et al., 2005; Wu et al., 2005) . For example, we and others have shown that inhibition of PKA activity (Coxon et al., 2005) , transfection of a dominantnegative A-CREB plasmid (Wu et al., 2005) , or transfection of CRE decoy oligonucleotides (ChoChung (2003) and unpublished data) results in variable MEC tumor growth inhibition. Targeting the etiologic translocation product, however, may offer enhanced efficacy and specificity. The recognition that cryptic chromosomal translocations with oncogenic 'gain-offunction' fusion oncogenes may play an increasing role in the genesis of other solid epithelial tumors such as prostate cancer (Tomlins et al., 2005) or secretory breast cancer (Tognon et al., 2002) , further emphasizes the need to develop new model systems and in vivo vector delivery strategies. Tumor growth in salivary gland cancers T Komiya et al
